<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112687">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01983566</url>
  </required_header>
  <id_info>
    <org_study_id>1241.44</org_study_id>
    <secondary_id>2013-003967-74</secondary_id>
    <nct_id>NCT01983566</nct_id>
  </id_info>
  <brief_title>Effect of Food and Increased Gastric pH Value on Bioavailability of a Single Dose of BI 207127 in Healthy Caucasian and Japanese Subjects</brief_title>
  <official_title>Investigation of the Effect of Food and of Increased Gastric pH on the Relative Bioavailability of Deleobuvir Following Single Oral Administration in Healthy Caucasian and Japanese Subjects (an Open-label, Randomised, Four-way Crossover Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to investigate the effect of food with different fat content
      and of gastric pH increase (mediated by multiple dosing of omeprazole) on the relative
      bioavailability of deleobuvir.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Area under the concentration-time curve of deleobuvir in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of deleobuvir in plasma (Cmax)</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of deleobuvir in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf)</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 207127 fasted</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient to receive BI 207127 as a single dose in fasted state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 207127 high fat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive BI 207127 as a single dose after a high fat breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 207127 low fat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive BI 207127 as a single dose after a low fat breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 207127 with Omeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive BI 207127 as a single dose after 4 days treatment with Omeprazole 40 mg once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127 high fat</intervention_name>
    <description>BI 207127 as a single dose after a high fat breakfast</description>
    <arm_group_label>BI 207127 high fat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127 with Omeprazole</intervention_name>
    <description>BI 207127 as a single dose after 4 days treatment of Omeprazole 40 mg once a day</description>
    <arm_group_label>BI 207127 with Omeprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127</intervention_name>
    <description>BI 207127 as a single dose in fasted state</description>
    <arm_group_label>BI 207127 fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127 low fat</intervention_name>
    <description>BI 207127 as a single dose after a low fat breakfast</description>
    <arm_group_label>BI 207127 low fat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy males or females according to the investigators assessment, as based on the
             following criteria: a complete medical history including a physical examination,
             vital signs (BP, PR), 12-lead ECG, and clinical laboratory tests. Subjects will be
             either Caucasian or Japanese (first generation Japanese: born in Japan with parents
             of Japanese descent, and not more than 5 years out of Japan, documented by medical
             interview and by appropriate materials - e.g. passport, birth certificate, etc)

          -  Age 20 to 35 years (incl.)

          -  BMI 18.5 to 25 kg/m2 (incl.)

        Exclusion criteria:

          -  Any finding in the medical examination (including BP, PR or ECG) deviating from
             normal and judged clinically relevant by the investigator

          -  Repeated measurement of systolic blood pressure greater than 140 mm Hg or diastolic
             blood pressure greater than 90 mm Hg

          -  Any laboratory value outside the reference range that the investigator considers to
             be of clinical relevance

          -  Any evidence of a concomitant disease judged clinically relevant by the investigator

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Surgery of the gastrointestinal tract that could interfere with kinetics of the study
             drug(s)

          -  Diseases of the central nervous system (such as epilepsy), other neurological
             disorders or psychiatric disorders
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1241.44.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 5, 2014</lastchanged_date>
  <firstreceived_date>November 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
